Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07780032
NA

Neuromodulation to Overcome Severe Restless Legs Syndrome

Sponsor: Marshall Holland

View on ClinicalTrials.gov

Summary

This prospective, single-center, first-in-indication feasibility study will evaluate the safety and preliminary effectiveness of spinal cord stimulation (SCS) for the treatment of severe, treatment-refractory primary Restless Legs Syndrome (RLS). Participants will undergo implantation of the Saluda Medical Evoke® Spinal Cord Stimulation System and will be followed for 24 months with clinical, neurophysiological, and patient-reported outcome assessments.

Official title: Neuromodulation to Overcome Severe Restless Legs Syndrome (NO RLS)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2027-10

Completion Date

2034-10

Last Updated

2026-10-09

Healthy Volunteers

No

Interventions

DEVICE

Spinal Cord Stimulation

Implantation of the FDA-approved Saluda Medical Evoke® Spinal Cord Stimulation System with Smartloop® Technology. Two percutaneous epidural leads will be implanted in the thoracic spine (T7-T10 region) and programmed to provide chronic spinal cord stimulation for treatment of severe RLS symptoms.

Locations (1)

UAB Hospital

Birmingham, Alabama, United States